Muscle Mass vs. Usable Strength: Why Muscle-Building Drugs Fall Short

September 9, 2026

•

Strength & Muscle

Share this post

A September 2026 Nature Reviews Drug Discovery review, as summarized by Rapamycin News, examines innovative treatments for sarcopenia. The researchers report that drug-driven gains in muscle mass often fail to produce equivalent improvements in physical strength.

The Study Methodology and Scope

The review evaluates a broad pharmacological pipeline designed to address age-related muscle decline. Researchers examined studies covering multiple treatment categories and diverse patient populations. To understand these physiological effects, the reviewers analyzed trials involving various clinical demographics. This included studies focused strictly on body composition, metabolic changes, and muscular function.

The bimagrumab monotherapy trials followed adults with type 2 diabetes and obesity over a 48-week period. Another key study was the 2026 BELIEVE phase 2 trial. This specific trial evaluated adults with overweight or obesity. By studying these populations, researchers could observe how different medications altered lean tissue during weight management.

The researchers also reviewed data from a separate 2026 systematic network meta-analysis. This network analysis focused directly on older adults with sarcopenia. It also included older adults at an elevated risk for age-related muscle loss. The review compares the pharmacological trial results with data on supervised resistance training in these exact populations.

By analyzing these different demographic groups, the reviewers compared pharmacological interventions against established physical training protocols. The available report does not provide a single standardized training protocol for this comparison. Instead, the comparison serves as a broad review conclusion rather than a direct trial result. This approach allowed researchers to evaluate the current state of muscle preservation science.

The Gap Between Muscle Quantity and Quality

The central finding is that increasing muscle mass through medication does not automatically improve physical capability. Myostatin-blocking antibodies represent the most advanced category of muscle-building drugs discussed in the report. These specific antibodies produced approximately 3% to 9% muscle-mass gains in human studies. However, the researchers noted that these physical gains came with limited functional improvements.

To contextualize these numbers, the reviewers provided a simple mathematical illustration. For a hypothetical person with 28 kilograms of lean mass, a 3% to 9% increase equals roughly 0.8 to 2.5 kilograms. This calculation is a mathematical illustration rather than a guaranteed clinical outcome. It demonstrates the expected scale of mass changes observed in the pharmacological trials.

The report stresses that muscle mass is an incomplete surrogate for muscle quality. A larger muscle measured by body-composition techniques is not automatically a stronger muscle. It does not automatically improve lifting capacity, walking speed, or recovery from illness. The force-producing fraction of the muscle appears to require mechanical tension.

Outcomes from Myostatin and Activin Inhibitors

Myostatin and activin signaling act as biological brakes on muscle growth. Bimagrumab is an antibody targeting activin type II receptors. It has been studied as a novel way to increase or preserve lean mass. The 2026 BELIEVE phase 2 study paired bimagrumab with semaglutide to test this concept.

In that trial, adding bimagrumab reduced the decline in total-body lean mass to approximately 2%. Meanwhile, patients using semaglutide alone saw a structural decline of approximately 7%. A separate report described the physical effects of bimagrumab monotherapy. This approach produced a 3.6% increase in lean mass over 48 weeks while reducing fat mass.

The reviewed pipeline also includes investigational medicines such as apitegromab. Trevogrumab is described as another potential candidate in the broader muscle-preservation pipeline. These agents are designed to block the signals that normally limit muscle expansion. The researchers found that simply removing these biological brakes does not build actual physical capability.

Findings on GLP-1 Treatments and Lean Tissue

The rapid growth of GLP-1 obesity treatments has intensified interest in preserving lean mass. Substantial weight loss can include the loss of lean functional tissue. Therefore, muscle preservation is an important clinical consideration during these systemic treatments. The emerging strategy is to combine incretin-based weight-loss drugs with muscle-preserving agents.

Current evidence in this medical area focuses heavily on body-composition measurements. Physical metrics like functional strength, basic mobility, and long-term independence remain less consistently assessed. The available literature states that resistance exercise remains the true foundation of muscle preservation during weight loss. Without structural loading, the body does not retain the capacity to generate peak force.

Adequate nutritional support is also a required factor for preserving active lean tissue. One 2026 review describes approximately 1.2 to 1.6 grams of protein per kilogram of body weight per day as a commonly cited range. This exact range is recommended when combined with regular resistance training. Protein needs should always be individualized for kidney health, total diet, and clinical status.

The Experimental Pipeline Outcomes

The pipeline reported in the Nature review extends far beyond myostatin inhibitors. It includes supplements or nutritional compounds such as urolithin A and nicotinamide riboside. The review also notes the presence of trigonelline and oleuropein. The researchers surveyed repurposed or investigational medicines like rapamycin analogues and tofacitinib.

Additional proposed approaches target chronic inflammation and cellular senescence. Other structural targets include mitochondrial function and the muscle satellite-cell niche. This reflects a shift toward treating earlier biological changes rather than just late-stage structural problems. However, inclusion in a drug-discovery review does not prove direct clinical effectiveness.

For several proposed interventions, the available sources describe biological rationale rather than established improvements. The pipeline includes inhibitors of 15-PGDH, which the review describes as a gerozyme. The current evidence focuses on early signals rather than established improvements in healthy aging.

Outcomes from Supervised Resistance Training

The report cleanly contrasts the pharmacological results with supervised resistance training. A separate 2026 systematic review and meta-analysis examined older adults with sarcopenia. This analysis found that resistance training significantly improved handgrip and knee-extension strength. These strength improvements occurred even when total skeletal muscle mass increases were not statistically significant.

This clear finding reinforces the distinction between muscle quantity and muscle performance. A network meta-analysis provided further data on structural exercise combinations. Combining resistance and balance training with protein-based nutrition improved grip strength, gait speed, and skeletal-muscle index. This was observed in older adults with sarcopenia or elevated risk.

The reported grip-strength improvement was 5.45 kilograms. This precise measurement had a 95 percent confidence interval of 3.58 to 7.33 kilograms. The gait-speed improvement was 0.20 metres per second. This improvement had a 95 percent confidence interval of 0.11 to 0.29 metres per second.

The same network analysis reported that resistance training combined with nutrition produced the largest gains in knee-extension strength. Because this was a network meta-analysis of selected studies, it is not proof of one universal optimal program. It places exercise and adequate protein at the benchmark for muscle health.

Practical Application of the Findings

The research outlines several practical applications for older men pursuing strength and muscle goals. Muscle programs should be judged by performance rather than superficial appearance or lean mass alone. Men should meticulously track practical outcomes such as the weight they can lift safely. Repeated chair stands, baseline walking pace, and physical balance are also critical indicators of capability.

Progressive resistance training must remain the absolute central focus. The available evidence supports resistance training as a highly reliable way to improve strength in older adults. Training should be supervised or heavily modified for joint problems, cardiovascular disease, or prior injury. This is critical for men recovering their energy and metabolism after long periods of inactivity.

Protein should be used as support for training rather than a replacement for it. A network meta-analysis found clear benefits from combining protein-based nutrition with functional exercise. Men using a GLP-1 medicine should discuss muscle preservation proactively with their clinician. Weight loss should be monitored with far more than a simple scale reading.

Clinicians may evaluate body composition, functional strength, and physical activity during weight loss. Investigational muscle drugs should be treated as strictly investigational. A product that reports a larger lean-mass measurement has not necessarily demonstrated better long-term mobility. Men should remain extremely cautious about broad muscle-building claims.

Structural Limitations and Clinical Caveats

The researchers noted several structural limitations within the current body of evidence. Bimagrumab studies largely involved adults with obesity rather than healthy older men. Therefore, the results cannot be directly generalized to men seeking mobility and recovery benefits. The available coverage does not establish that these agents are approved for routine prevention of age-related sarcopenia.

Functional outcomes in studies like the BELIEVE trial were mostly secondary or exploratory. The evidence does not establish that preservation of lean mass improves true physical performance or independence. A separate review argues that the force-producing fraction of muscle should be treated as a targeted therapeutic goal. Clinical trials should be designed to test this directly using established functional endpoints.

The mass-versus-function distinction should not be exaggerated into a claim that mass does not matter. Low muscle mass can be associated with early frailty and impaired metabolic health. The researchers conclude that lean mass is necessary but strictly insufficient as a measure of successful treatment. A therapy should ideally demonstrate improvements in strength, mobility, and daily function.

Pharmacological approaches could eventually be useful for people who cannot train adequately. This includes individuals dealing with chronic illness, severe frailty, or rapid weight loss. For a healthy older adult capable of lifting, medications remain mere potential adjuncts. They should be used under medical supervision, never as absolute substitutes for training.

This research confirms that pharmacological approaches to muscle building remain strictly adjunctive, reinforcing that supervised resistance training combined with adequate protein intake is still the required foundation for functional strength.

How Everfitguys helps

Declining focus, memory and mental sharpness often prompt older men to look for medical shortcuts, but relying on medication alone rarely builds true physical reserve. Mistaking superficial mass gains for functional capability creates a false sense of security, and Everfitguys analyzes clinical evidence to help mature men build actual usable strength safely. Read the research